203 related articles for article (PubMed ID: 33008436)
1. Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease.
Ahmad S; Orellana A; Kohler I; Frölich L; de Rojas I; Gil S; Boada M; Hernández I; Hausner L; Bakker MHM; Cabrera-Socorro A; Amin N; Ramírez A; Ruiz A; Hankemeier T; Van Duijn CM
Alzheimers Res Ther; 2020 Oct; 12(1):124. PubMed ID: 33008436
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
3. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
5. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
6. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
7. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
[TBL] [Abstract][Full Text] [Related]
8. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
10. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status.
Marizzoni M; Ferrari C; Babiloni C; Albani D; Barkhof F; Cavaliere L; Didic M; Forloni G; Fusco F; Galluzzi S; Hensch T; Jovicich J; Marra C; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Ranjeva JP; Ribaldi F; Rolandi E; Rossini PM; Salvatore M; Soricelli A; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB
Neurobiol Aging; 2020 May; 89():55-62. PubMed ID: 32029236
[TBL] [Abstract][Full Text] [Related]
11. Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.
Gabriel AJ; Almeida MR; Ribeiro MH; Carneiro D; Valério D; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
J Alzheimers Dis; 2018; 61(3):1097-1105. PubMed ID: 29254094
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J
J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer's disease.
Dakterzada F; Jové M; Huerto R; Carnes A; Sol J; Pamplona R; Piñol-Ripoll G
Geroscience; 2024 Feb; 46(1):683-696. PubMed ID: 37999901
[TBL] [Abstract][Full Text] [Related]
14. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
15. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
[TBL] [Abstract][Full Text] [Related]
16. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
[TBL] [Abstract][Full Text] [Related]
17. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
18. Sex differences in CSF biomarkers vary by Alzheimer disease stage and
Babapour Mofrad R; Tijms BM; Scheltens P; Barkhof F; van der Flier WM; Sikkes SAM; Teunissen CE
Neurology; 2020 Oct; 95(17):e2378-e2388. PubMed ID: 32788242
[TBL] [Abstract][Full Text] [Related]
19. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
20. Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis.
Eppig JS; Edmonds EC; Campbell L; Sanderson-Cimino M; Delano-Wood L; Bondi MW;
J Int Neuropsychol Soc; 2017 Aug; 23(7):564-576. PubMed ID: 28578726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
